<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00374660</url>
  </required_header>
  <id_info>
    <org_study_id>IROF-017</org_study_id>
    <nct_id>NCT00374660</nct_id>
  </id_info>
  <brief_title>Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I-II Clinical and Pharmacokinetic Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose (MTD) and to investigate&#xD;
      the efficacy, safety and pharmacokinetics of irofulven combined with oxaliplatin in patients&#xD;
      with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2003</start_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed response rate: Hepatocellular Cancer (HCC) Cohort: Response Evaluation Criteria in Solid Tumors (RECIST) criteria.</measure>
    <time_frame>Every 8 weeks until progression.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hormone Refractory Prostate Cancer (HRPC) Cohort: Prostate-Specific Antigen Working Group Recommendations (PSAWGR) and RECIST criteria.</measure>
    <time_frame>Every 8 weeks until progression.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: HRPC Cohort: confirmed response rate according to RECIST; progression-free survival (PFS) for progression according to RECIST; new bone lesions or skeletal events; PFS according to PSA progression; overall survival.</measure>
    <time_frame>Every 8 weeks until progression.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: HCC cohort - PFS (RECIST); overall survival</measure>
    <time_frame>Every 8 weeks until progression.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irofulven + oxaliplatin</intervention_name>
    <description>Oxaliplatin will be administered in a 2-hour infusion on Days 1 and 15 of a 28-day cycle. Starting dose 40 mg/m^2, dose escalation 50, 60, 70, and 80 mg/m^2 every 28 days if no dose-limiting toxicity.&#xD;
Thirty minutes after completion of oxaliplatin infusion, irofulven will be administered in a 30-minute infusion on Days 1 and 15 of a 28-day cycle. Starting dose 0.30 mg/kg, dose escalation to 0.40 mg/kg every 28 days if no dose-limiting toxicity.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent obtained prior to initiation of any study-specific procedures&#xD;
             and treatment.&#xD;
&#xD;
          2. Malignant solid tumor confirmed by a biopsy sample.&#xD;
&#xD;
          3. Pancreatic, endometrial, gastric, and hepatocellular cancer patients that have&#xD;
             exhausted standard treatment options.&#xD;
&#xD;
          4. Measurable disease according to RECIST.&#xD;
&#xD;
          5. 18 years of age or older.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0-1.&#xD;
&#xD;
          7. Life expectancy greater than 3 months.&#xD;
&#xD;
          8. Previous anticancer treatment must be discontinued at least 4 weeks prior to first&#xD;
             dose of study treatment (6 weeks for mitomycin C, 8 weeks for bicalutamide).&#xD;
&#xD;
          9. Patients of reproductive age must be using effective contraceptive methods.&#xD;
&#xD;
         10. Negative pregnancy test for patients of reproductive potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior therapy with irofulven or oxaliplatin.&#xD;
&#xD;
          2. Patients who have had radiation therapy to more than 30% of the bone marrow prior to&#xD;
             entry into the study.&#xD;
&#xD;
          3. Prior chemotherapy with nitrosoureas or high dose carboplatin (AUC &gt; 6), prior&#xD;
             mitomycin C cumulative dose greater than or equal to 25 mg/mÂ², prior bone marrow&#xD;
             transplant or intensive chemotherapy with stem cell support.&#xD;
&#xD;
          4. Presence of any serious concomitant systemic disorders incompatible with the study&#xD;
             (e.g., uncontrolled congestive heart failure, active infection).&#xD;
&#xD;
          5. Any previous history of another malignancy (other than cured basal cell carcinoma of&#xD;
             the skin or cured in-situ carcinoma of the cervix) within 5 years of study entry,&#xD;
             unless the active malignancy can be unmistakably identified by evidence such as recent&#xD;
             biopsies or tumor specific markers.&#xD;
&#xD;
          6. Treatment with any other investigational agent, or participation in another clinical&#xD;
             trial within 28 days prior to study entry.&#xD;
&#xD;
          7. Pregnant or lactating patients or any patient with childbearing potential not using&#xD;
             adequate contraception.&#xD;
&#xD;
          8. Patients with retinopathy or significant visual impairment not correctable by&#xD;
             refractory lens will be enrolled on a case by case basis according to the expected&#xD;
             benefit ratio, taking into account the malignant disease and the existence of an&#xD;
             objective decreased visual acuity and its degree.&#xD;
&#xD;
        Please note: There are additional criteria that must be met in order to be eligible for&#xD;
        this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>September 8, 2006</study_first_submitted>
  <study_first_submitted_qc>September 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2006</study_first_posted>
  <last_update_submitted>June 30, 2015</last_update_submitted>
  <last_update_submitted_qc>June 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irofulven</keyword>
  <keyword>Oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irofulven</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

